At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 15 enrolled
Drug / intervention
Insulin Peglispro +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of the Effects of LY2605541 on Triglyceride Metabolism, Compared to Insulin Glargine, in Patients With Type 1 Diabetes Mellitus
In Brief
A Phase 1 clinical trial evaluating Insulin Peglispro and Insulin Glargine for Diabetes Mellitus, Type 1. Completed, enrolled 15 participants across 1 site.
Detailed Summary
This study has two parts. Each participant will receive a daily injection of insulin peglispro during one treatment period and a daily injection of insulin glargine during the other treatment period. Each treatment period is 3 to 4 weeks and is followed by procedures to look at how the body uses or stores fats while taking each study drug.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1
CountriesDenmark
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 2013
Enrollment StartOct 2013
Primary CompletionDec 2014
TodayJul 2026
First PostedJan 18, 2013
Enrollment StartOct 1, 2013
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 13.5 years ago
Interventions
Insulin Peglisprobiological
Daily doses administered SC.
Insulin Glarginebiological
Daily doses administered SC.